• Faeth Therapeutics presented preclinical PIKTOR results in HR-positive, HER2-negative breast cancer models at the ESMO Congress 2026 in Madrid.
• Oral PIKTOR matched or exceeded intravenous gedatolisib in suppressing tumor growth in mouse models.
• Combined with fulvestrant and palbociclib, PIKTOR halted tumor growth in one model and shrank tumors in another.
• The findings support the ongoing Phase 1b/2 FTH-PIK-101 breast cancer trial, with interim data expected in 2027.
• Topline results from Phase 2 FTH-PIK-201 in second-line advanced endometrial cancer are expected by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023657226) on October 23, 2026, and is solely responsible for the information contained therein.